minimal residual disease | International Myeloma Foundation

blog imwg 2020 summary

Week in Review

August 27

The 11th Annual IMWG Summit— A Great Success

ASCO 2020 clinical implications of MRD negativity

June 7

Clinical implications of loss of minimal residual disease (MRD) negativity in multiple myeloma

ASCO abstract 8513

June 5

MRD assessed by mass spectrometry versus next generation sequencing in bone marrow in myeloma pts treated with KRd+ASCT

ASk Dr Durie MRD in Clinical Trials

December 12

Is minimal residual disease (MRD) testing routinely recommended for myeloma patients?

File folders with a magnifying glass

Week in Review

November 21

ASH 2019 Update: Late-Breaking Abstracts and Hot-Topic Posters

photo of Amsterdam

Week in Review

May 23

Why the IMWG Summit Is So Important

Ask Dr Durie MRD Remission

May 23

If the MRD test is negative, is that always a good predictor of a longer remission?

Highway sign with the word "cure"

Week in Review

May 2

The future looks bright—including a cure for myeloma

Researcher looks at a slide sample next to a microscope.

Week in Review

December 27

FDA Approvals and Prize-Winning Research Are Welcome Good News for Myeloma Patients

Group photo with members from the IMF'S Asian Myeloma Network

Week in Review

October 25

Second Asian Myeloma Network Summit in Beijing, China Is a Big Success

Video still of the Ask Dr. Durie episode

October 11

How does the FDA approval of next-generation sequencing (NGS) to test for MRD in multiple myeloma affect patients?

Cells magnified under a microscope.

Week in Review

April 12

Black Swan researchers identify good-risk and poor-risk MRD patients, China’s ‘disruptive’ biotech, and reasons to eat ‘real food’

Subscribe to minimal residual disease

Give Where Most Needed